The drugmaker attributes the forecasted revenue and adjusted earnings to a strong demand for its recently launched diabetes and psoriasis drugs. In addition, the company expects additional progress in its drug portfolio in 2018, including a new rheumatoid arthritis treatment.
Even though Eli Lilly has seen increased competition from biosimilars entering the market, the company reaffirmed its expectation of at least a 5 percent annual revenue growth rate from 2015 to 2020.
More articles on supply chain:
10 recent pharma layoffs
Sanofi urges Philippine government to lift suspension of its dengue vaccine
Medline to relocate supply distribution center in Maryland, triple its workforce
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
